Wedbush raised its price target on Blueprint Medicines (NASDAQ: BPMC) to $98.00 (from $96.00) while maintaining a Outperform rating.Analyst David ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Blueprint Medicines (BPMC) PT Raised to $96 at Canaccord Genuity; 'Catalyst-rich 2018; data flow from all programs'February 22, 2018 5:24 AM Form S-8 Blueprint Medicines Corp February 21, 2018 6:00 PM Form 10-K Blueprint Medicines Corp For: Dec 31February 21, 2018 6:00 PM Form 8-K Blueprint Medicines Corp For: Feb 21February 21, 2018 7:32 AM Blueprint Medicines (BPMC) Misses Q4 EPS by 12c, Miss on RevenuesFebruary 21, 2018 7:07 AM Blueprint Medicines Reports Fourth Quarter and Full Year 2017 Financial ResultsFebruary 21, 2018 7:01 AM